Evaluation of Antidepressant Effects of Silibinin Alone and in Combination with Sertraline and Venlafaxine in Swiss Albino Mice
Depression is a major psychiatric disorder characterized by persistent low mood, anhedonia, and impaired functioning. Current antidepressant therapies are often limited by delayed onset and incomplete response. The present study evaluated the antidepressant-like effects of Silibinin alone and in combination with Sertraline and Venlafaxine in a Chronic Unpredictable Mild Stress (CUMS) model in Swiss albino mice. Animals were divided into seven groups and subjected to CUMS for 6 weeks, with drug treatment administered from day 22 to day 42. Antidepressant activity was assessed using the Forced Swim Test (FST), Tail Suspension Test (TST), Sucrose Preference Test (SPT), Actophotometer, and Coat State scoring. CUMS exposure significantly increased immobility time in the FST (143.2 ± 6.18 s) and TST (155.5 ± 10 s) and reduced sucrose consumption (4.842 ± 0.5358 ml), indicating behavioral despair and anhedonia. Treatment with Silibinin (100 mg/kg), Sertraline (5 mg/kg), and Venlafaxine (16 mg/kg) significantly improved these parameters. Notably, combination therapy produced superior effects, with the Silibinin–Venlafaxine group showing the greatest reduction in immobility (68.0 ± 5.44 s in FST; 88.5 ± 4.7 s in TST) and the highest sucrose consumption (12.26 ± 0.817 ml). Combinationtreated groups also demonstrated enhanced swimming and climbing behaviors. Locomotor activity analysis confirmed the absence of nonspecific CNS stimulant effects, while coat state deterioration induced by CUMS was significantly reversed in all treated groups. Major Findings: The findings suggest that Silibinin possesses significant antidepressant-like activity and enhances the efficacy of conventional antidepressants, with the Silibinin–Venlafaxine combination showing superior outcomes.